Galena Biopharma, Inc. (NASDAQ: GALE) anounced the Company has confirmed the regulatory pathway to advance GALE-401 (Anagrelide Controlled Release) into ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE